Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

NCT01142661 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01142661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01142661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
Lead sponsor
Eisai Inc.
Phase
Not applicable
Overall status
Completed
Start date
August 31, 2010
Completion date
Not reported
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer